X4 PHARMACEUTICALS, INC
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2015 | — | $-34.3M | $7.1M |
| Dec 2016 | — | $-23.1M | $15.2M |
| Mar 2017 | — | — | $2.3M |
| Jun 2017 | — | — | $24.1M |
| Sep 2017 | — | — | $26.3M |
| Dec 2017 | — | $-44.5M | $26.7M |
| Mar 2018 | — | $-51.8M | $64.0M |
| Jun 2018 | — | $-57.7M | $12.6M |
| Sep 2018 | — | $-66.1M | $9.8M |
| Dec 2018 | $8.3M | $-77.1M | $8.1M |
| Mar 2019 | $14.2M | $29.4M | $22.3M |
| Jun 2019 | $22.2M | $96.2M | $90.2M |
| Sep 2019 | $20.0M | $79.1M | $76.3M |
| Dec 2019 | $20.0M | $129.2M | $126.2M |
| Mar 2020 | $25.0M | $118.8M | $115.1M |
| Jun 2020 | $25.0M | $104.9M | $103.7M |
| Sep 2020 | $25.0M | $89.7M | $88.8M |
| Dec 2020 | $33.2M | $72.8M | $78.7M |
| Mar 2021 | $32.5M | $105.1M | $114.9M |
| Jun 2021 | $32.5M | $87.3M | $95.2M |
| Sep 2021 | $32.5M | $68.7M | $76.4M |
| Dec 2021 | $33.1M | $64.4M | $81.8M |
| Mar 2022 | $32.5M | $49.7M | $66.4M |
| Jun 2022 | $32.5M | $30.1M | $47.4M |
| Sep 2022 | $32.5M | $61.8M | $79.9M |
| Dec 2022 | $32.3M | $74.1M | $121.7M |
| Mar 2023 | $32.5M | $51.7M | $93.4M |
| Jun 2023 | $32.5M | $67.5M | $136.4M |
| Sep 2023 | $55.0M | $67.6M | $131.6M |
| Dec 2023 | $54.6M | $51.1M | $99.2M |
| Mar 2024 | $55.0M | $1.0M | $60.5M |
| Jun 2024 | $75.0M | $94.5M | $147.2M |
| Sep 2024 | $75.0M | $59.6M | $97.4M |
| Dec 2024 | $75.0M | $22.1M | $55.7M |
| Mar 2025 | $75.0M | $22.9M | $40.3M |
| Jun 2025 | $75.0M | $4.0M | $39.2M |
| Sep 2025 | $75.0M | $61.6M | $69.6M |
| Dec 2025 | $75.0M | $186.3M | $217.0M |
| Mar 2026 | $75.0M | $168.5M | $216.9M |
| Jun 2026 | $75.0M | $155.5M | $195.1M |